Plans to expand facilities to increase anticancer drug production: interview with Kamiwatari (神渡), president of Nippon Kayaku Pharma Tech

Nippon Kayaku Pharma Tech plans to expand facilities to increase anticancer drug production after acquiring the Fuji Yakuhin Toyama No. 2 Plant, which provides contract manufacturing of anticancer drugs.

Read in fullFrom the source, not the headline

sources corroborateOutlets reporting the same event

companies linkedAcross 0 themes, second pass

The story

Nippon Kayaku Pharma Tech acquired the Fuji Yakuhin Toyama No. 2 Plant (Itakura, Fuchu-machi, Toyama City).

The plant has provided contract manufacturing of injectable drugs.

Following the acquisition, the company is reported to be planning to expand facilities to increase anticancer drug production.

At a glance

Acquisition targetAcquired the Fuji Yakuhin Toyama No. 2 Plant

PlantFuji Yakuhin Toyama No. 2 Plant (Itakura, Fuchu-machi, Toyama City)

TypeAcquired a plant that has provided contract manufacturing of injectable drugs

PurposePlans to expand facilities to increase anticancer drug production

Reference information. Every claim resolves to something the story actually named.

Where this came from

We read each source in full and checked they agree on the core claim.

1/ 1 agree

All of them report the same thing.

google.comNews

AgreesOpen

Read the original articleGo to the source page

Reference information generated from public sources. It does not solicit or advise on investments. Prices are 15-minute delayed.